- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01247831
The Effect of Selective Laser Trabeculoplasty (SLT) on Ocular Rigidity (SLT/ORA)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Ocular Rigidity (corneal hysteresis and corneal resistance factor) is measured with the Ocular Response Analyzer (Reichert) before and 4 weeks after SLT (Q-switched 532 nm frequency doubled neodymium yttrium aluminium garnet laser with a spot size of 400 µm and a 3-ns pulse duration). The trabecular meshwork is treated with 100 spots over 360° and an energy of 0,8 mJ.
The purpose is to examine if selective laser trabeculoplasty changes ocular rigidity.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Saxonia
-
Dresden, Saxonia, Germany, 01307
- University Eye Clinic Dresden
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
glaucoma patients (primary open angle glaucoma, ocular hypertension) over the age of 18 who need further IOP reduction to control their glaucoma
Exclusion Criteria:
other forms of glaucoma (angle closure, secondary glaucoma, congenital, juvenile), acute psychosis, epilepsy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: glaucoma patients
All of the patients treated with SLT need further IOP reduction for control of their glaucoma.
|
100 spots with an energy of 0,8 mJ are applied over 360° of the trabecular meshwork of glaucoma patients with a Q-switched 532 nm frequency doubled neodymium YAG Laser.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change in ocular rigidity
Time Frame: 4 weeks
|
Is there a change in ocular rigidity (corneal hysteresis, corneal resistance factor) as measured with the Ocular Response Analyzer (Reichert) after selective laser trabeculoplasty?
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
IOP reduction
Time Frame: 4 weeks
|
Is there an effective IOP drop after SLT?
|
4 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Karin R Hornykewycz, MD, University Eye Clinic Dresden
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SLT/ORA/1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glaucoma
-
Imperial College Healthcare NHS TrustIRIDEX CorporationNot yet recruitingGlaucoma | Glaucoma, Open-Angle | Glaucoma, Angle-Closure | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma Secondary | Glaucoma Traumatic | Glaucoma Uveitic
-
Wills EyeIOP OphthalmicsTerminatedPrimary Open Angle Glaucoma | Neovascular Glaucoma | Uveitic Glaucoma | Pseudoexfoliation Glaucoma | Primary Angle Closure Glaucoma | Pigmentary Glaucoma | Traumatic GlaucomaUnited States
-
Centre hospitalier de l'Université de Montréal...CompletedGlaucoma | Glaucoma, Open-Angle | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma and Ocular Hypertension | Glaucoma, Uncompensated | Glaucoma SecondaryCanada
-
Pro Top & Mediking Company LimitedCompletedOpen Angle Glaucoma | Neovascular Glaucoma | Angle Closure Glaucoma | Uveitis Glaucoma | Young Age Glaucoma | High Risk PatientEstonia
-
Sanoculis LtdCompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaIsrael
-
Bausch & Lomb IncorporatedNicOx Inc.CompletedPrimary Open Angle Glaucoma | Ocular Hypertension | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaUnited States
-
Sensimed AGCompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaFrance
-
Wills EyeOptovueCompletedPrimary Open-angle Glaucoma | Normal Tension Glaucoma | Glaucoma; DrugsUnited States
-
Ivantis, Inc.CompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaUnited States
-
University of California, San FranciscoUniversity of Colorado, Denver; University of Maryland; Zhongshan Ophthalmic... and other collaboratorsCompletedPrimary Open Angle Glaucoma | Glaucoma | Neovascular Glaucoma | Secondary GlaucomaUnited States, China, India, Mexico
Clinical Trials on Selective Laser Trabeculoplasty
-
Belkin Laser Ltd.CompletedOpen Angle GlaucomaGeorgia
-
Western University, CanadaCompletedOcular Hypertension | Intraocular Pressure | Primary Open Angle Glaucoma of Both EyesCanada
-
Queen's UniversityTerminated
-
University of ZurichCompletedOcular Hypertension | Cataract | Open Angle GlaucomaSwitzerland
-
University Hospital, GenevaTerminatedGlaucoma and Ocular HypertensionSwitzerland
-
Sunnybrook Health Sciences CentreCompleted
-
Jayme ViannaGlaucoma Research Society of Canada; Canadian Glaucoma SocietyNot yet recruitingPseudoexfoliation Glaucoma
-
West Virginia UniversityCompletedGlaucomaUnited States
-
University of TorontoUniversity of Western Ontario, CanadaUnknown
-
Glaucoma Research & Education GroupPharmaLogic Development, Inc.UnknownPrimary Open Angle Glaucoma | Ocular Hypertension | Pigment Dispersion Glaucoma | Pseudo-Exfoliative GlaucomaUnited States